Connect Biopharma Holdings Limited financials
$0.9920−8.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $64.0K | $26.0M | $0.00 | $0.00 | $0.00 |
| Gross profit | $64.0K | $26.0M | $0.00 | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | — | — | — |
| Operating income | -$58.1M | -$22.5M | -$69.1M | -$120.2M | -$101.1M |
| Net income | -$55.5M | -$15.6M | -$62.1M | -$118.1M | -$202.3M |
| Net margin | −86687.5% | −60.0% | — | — | — |
| Diluted EPS | $-1.00 | $-0.28 | $-1.13 | $-2.15 | $-3.88 |
| EBITDA | -$57.4M | -$21.8M | -$68.3M | -$114.8M | -$100.6M |
| Operating cash flow | -$51.2M | -$23.6M | -$47.7M | -$101.5M | -$84.3M |
| Free cash flow | -$51.6M | -$24.4M | -$47.8M | -$105.9M | -$88.2M |
| Diluted shares | 55.7M | 55.2M | 55.1M | 55.0M | 52.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $38.3M | $78.2M | $105.7M | $79.0M | $267.7M |
| Short-term investments | $6.0M | $15.5M | $12.6M | $73.4M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $56.1M | $101.3M | $127.4M | $174.0M | $291.1M |
| Total liabilities | $14.1M | $9.1M | $25.9M | $16.5M | $18.8M |
| Shareholders' equity | $42.0M | $92.2M | $101.5M | $157.5M | $272.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology